JFG
NKTR icon

Jefferies Financial Group’s Nektar Therapeutics NKTR Stock Holding History

Jefferies Financial Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-111,900
Closed -$4.73M – 2061
2025
Q4 		$4.73M Sell
111,900
-191,300
-63% -$10.7M 0.02% 498
2025
Q3 		$17.3M Buy
+303,200
New +$10M 0.08% 161

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jefferies Financial Group's NKTR Position: Q1 2026 in Review

Jefferies Financial Group sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 111,900 shares — an estimated $4.73M sold.

Jefferies Financial Group first reported a position in NKTR in Q3 2025 and held it in 2 quarters. The position peaked at $17.3M in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Jefferies Financial Group reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 111,900 Nektar Therapeutics shares in Q1 2026, an estimated $4.73M.
  • Jefferies Financial Group first reported a position in Nektar Therapeutics in Q3 2025 and held it in 2 quarters.
  • Jefferies Financial Group's Nektar Therapeutics position peaked at $17.3M in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.